Mechanism of the antitumoral activity of deferasirox, an iron chelation agent, on mantle cell lymphoma

Leukemia and Lymphoma

Volumn 54, Issue 4, 2013, Pages 851-859

  Vazana Barad, Liat ^a   Granot, Galit ^b   Mor Tzuntz, Rahav ^b   Levi, Itai ^c   Dreyling, Martin ^d   Nathan, Ilana ^a,c   Shpilberg, Ofer ^b  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Deferasirox; Iron chelators; Mantle cell lymphoma

Indexed keywords

CASPASE 3; CYCLIN D1; DEFERASIROX; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; G1 PHASE CELL CYCLE CHECKPOINT; IC 50; IRON CHELATION; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOATES; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN D1; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IRON; IRON CHELATING AGENTS; LYMPHOMA, MANTLE-CELL; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; RNA, MESSENGER; TRIAZOLES;

EID: 84879529296     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.734614     Document Type: Article

References (42)

1. Jares P, Campo E. Advances in the understanding of mantle cell lymphoma. Br J Haematol 2008; 142: 149-165.
2. Dreyling M, Hiddemann W. Current treatment standards and emerging strategies in mantle cell lymphoma. Hematology Am Soc Hematol Educ Program 2009: 542-451.
3. Ghielmini M, Zucca E. How I treat mantle cell lymphoma. Blood 2009; 114: 1469-1476.
4. Dreyling M, Hiddemann W. Dose-intense treatment of mantle cell lymphoma: Can durable remission be achieved? Curr Opin Oncol 2008; 20: 487-494.
5. Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone signifi cantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005; 23: 1984-1992.
6. Khouri IF, Lee MS, Saliba RM, et al. Nonablative allogeneic stemcell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 2003; 21: 4407-4412.
7. Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006; 24: 4867-4874.
8. Hoy S M, McKeage K. T emsirolimus: In relapsed and/or refractory mantle cell lymphoma. Drugs 2010; 70: 1819-1829.
9. Lin TS, Blum KA, Fischer DB, et al. Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders. J Clin Oncol 2010; 28: 418-423.
10. Le NT, Richardson DR. The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim Biophys Acta 2002; 1603: 31-46.
11. Richardson DR, Kalinowski DS, Lau S, et al. Cancer cell iron metabolism and the development of potent iron chelators as antitumour agents. Biochim Biophys Acta 2009; 1790: 702-717.
12. Prutki M, Poljak-Blazi M, Jakopovic M, et al. Altered iron metabolism, transferrin receptor 1 and ferritin in patients with colon cancer. Cancer Lett 2006; 238: 188-196.
13. Prior R, Reifenberger G, Wechsler W. T ransferrin receptor expression in tumours of the human nervous system:relation to tumour type, grading and tumour growth fraction. Virchows Arch A Pathol Anat Histopathol 1990; 416: 491-496.
14. Habashy HO, Powe DG, Staka CM, et al. Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen. Breast Cancer Res Treat 2010; 119: 283-293.
15. Dowlati A, Loo M, Bury T, et al. Soluble and cell-associated transferrin receptor in lung cancer. Br J Cancer 1997; 75: 1802-1806.
16. Lepelletier Y, Camara-Clayette V, Jin H, et al. Prevention of mantle lymphoma tumor establishment by routing transferrin receptor toward lysosomal compartments. Cancer Res 2007; 67: 1145-1154.
17. Ek S, Bjorck E, Porwit-MacDonald A, et al. Increased expression of Ki-67 in mantle cell lymphoma is associated with de-regulation of several cell cycle regulatory components, as identifi ed by global gene expression analysis. Haematologica 2004; 89: 686-695.
18. Noulsri E, Richardson DR, Lerdwana S, et al. Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells. Am J Hematol 2009; 84: 170-176.
19. Simonart T, Boelaert JR, Mosselmans R, et al. Antiproliferative and apoptotic Effects of iron chelators on human cervical carcinoma cells. Gynecol Oncol 2002; 85: 95-102.
20. Okada T, Sawada T, Kubota K. D eferoxamine enhances antiproliferative Effect of interferon-gamma against hepatocellular carcinoma cells. Cancer Lett 2007; 248: 24-31.
21. Brard L, Granai CO, Swamy N. Iron chelators deferoxamine and diethylenetriamine pentaacetic acid induce apoptosis in ovarian carcinoma. Gynecol Oncol 2006; 100: 116-127.
22. Yu Y, Kovacevic Z, Richardson D R. T uning cell cycle regulation with an iron key. Cell Cycle 2007; 6: 1982-1994.
23. Cappellini MD. Exjade(R) (deferasirox, ICL670) in the treatment of chronic iron overload associated with blood transfusion. Ther Clin Risk Manag 2007; 3: 291-299.
24. Nick H, Acklin P, Lattmann R, et al. Development of tridentate iron chelators: From desferrithiocin to ICL670. Curr Med Chem 2003; 10: 1065-1076.
25. Zelig U, Kapelushnik J, Moreh R, et al. Diagnosis of cell death by means of infrared spectroscopy. Biophys J 2009; 97: 2107-2114.
26. Hallak M, Win T, Shpilberg O, et al. The anti-leukaemic activity of novel synthetic naphthoquinones against acute myeloid leukaemia: Induction of cell death via the triggering of multiple signalling pathways. Br J Haematol 2009; 147: 459-470.
27. Enari M, Talanian RV, Wong WW, et al. Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis. Nature 1996; 380: 723-726.
28. Tashiro E, Tsuchiya A, Imoto M. Functions of cyclin D1 as an oncogene and regulation of cyclin D1 expression. Cancer Sci 2007; 98: 629-635.
29. Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: A randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2003; 361: 1597-1602.
30. Kalinowski DS, Richardson DR. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev 2005; 57: 547-583.
31. Cappellini MD. Long-term Efficacy and safety of deferasirox. Blood Rev 2008; 22(Suppl. 2): S35-S41.
32. Lalande M. A reversible arrest point in the late G1 phase of the mammalian cell cycle. Exp Cell Res 1990; 186: 332-339.
33. Hoyes KP, Hider RC, Porter JB. Cell cycle synchronization and growth inhibition by 3-hydroxypyridin-4-one iron chelators in leukemia cell lines. Cancer Res 1992; 52: 4591-4599.
34. Chantrel-Groussard K, Gaboriau F, Pasdeloup N, et al. The new orally active iron chelator ICL670A exhibits a higher antiproliferative Effect in human hepatocyte cultures than O-trensox. Eur J Pharmacol 2006; 541: 129-137.
35. Hallak M, Vazana L, Shpilberg O, et al. A molecular mechanism for mimosine-induced apoptosis involving oxidative stress and mitochondrial activation. Apoptosis 2008; 13: 147-155.
36. Nurtjahja-Tjendraputra E, Fu D, Phang JM, et al. Iron chelation regulates cyclin D1 expression via the proteasome: A link to iron defi ciency-mediated growth suppression. Blood 2007; 109: 4045-4054.
37. Darnell G, Richardson DR. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: The Effect of the ligands on molecular targets involved in proliferation. Blood 1999; 94: 781-792.
38. Klier M, Anastasov N, Hermann A, et al. Specific lentiviral shRNAmediated knockdown of cyclin D1 in mantle cell lymphoma has minimal Effects on cell survival and reveals a regulatory circuit with cyclin D2. Leukemia 2008; 22: 2097-2105.
39. Kornmann M, Arber N, Korc M. Inhibition of basal and mitogenstimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum. J Clin Invest 1998; 101: 344-352.
40. Ohyashiki JH, Kobayashi C, Hamamura R, et al. The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1. Cancer Sci 2009; 100: 970-977.
41. Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27: 3822-3829.
42. Messa E, Carturan S, Maff e C, et al. Deferasirox is a powerful NFkappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. Haematologica 2010; 95: 1308-1316.